News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
INNOVENT BIO 1Q Product Revenue Soars 50%+ YoY to RMB3.8B+
INNOVENT BIO (01801.HK) announced that its total product revenue amounted to over RMB3.8 billion in 1Q26, representing a robust YoY growth of over 50%.The company's oncology le...
Reset
Send
The window will close in 5 seconds
INNOVENT BIO 1Q Product Revenue Soars 50%+ YoY to RMB3.8B+
Close
Recommend
8
Positive
11
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get 1 Intel/Selected Gold ETF share!

INNOVENT BIO (01801.HK)  +8.500 (+11.356%)    Short selling $421.45M; Ratio 15.692%   announced that its total product revenue amounted to over RMB3.8 billion in 1Q26, representing a robust YoY growth of over 50%.

The company's oncology leadership became increasingly evident with the rapid commercial uptake of the five TKI (tyrosine kinase inhibitor) therapies newly included in the National Reimbursement Drug List (NRDL).

Related News M Stanley: Risk-Reward of China Biotech Stocks to Improve in 2H2026
Meanwhile, general biomedicine franchise has emerged as a powerful new growth driver, fueled by the strong performance of anchor assets, including mazdutide, SINTBILO(R) (tafolecimab injection), and SYCUME(R) (teprotumumab N01 injection).
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-29 16:25.)

Auto-translated by AI
View Original Text
This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.